Clinicians continue to treat resistant gram-negative infections with older, generic antibiotics that are considered to be less effective and less safe, even though FDA has approved seven next-generation gram-negative antibiotics between 2014 and 2019.

States have adopted their own laws to regulate PBMs, according to a new report from the U.S Government Accountability Office (GAO).

Pneumonia remains the most common infection-related condition that lands U.S. patients in the hospital. Identifying strategies to curb antibiotic overuse for those hospitalized with pneumonia continues to be a national priority.

Results of a new study published in NEJM found that semaglutide led to greater reductions in weight loss and heart failure–related symptoms in patients who had obesity-related heart failure with preserved ejection fraction and T2D compared with placebo.

Biosimilars have typically been viewed as cost-saving medications, but according to results of a study published in JAMA Health Forum, biosimilar competition did not consistently lower out-of-pocket costs for outpatients who were commercially insured. In fact, in some cases, costs even increased.